Vaheh Oganesyan

Vaheh Oganesyan

Auto-generated profile, based on publicly available information

Vaheh Oganesyan

Http://orcid.org

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 April 2019 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
JKJodi L. Karnell
Jodi L. Karnell
MAMarius Albulescu
Marius Albulescu
SDStacey Drabic
Stacey Drabic
LWLiangwei Wang
Liangwei Wang
RMRachel Moate
Rachel Moate
JDJörn Drappa
Jörn Drappa
The CD40/CD40L axis plays a central role in the generation of humoral immune responses and is an attractive target for treating autoimmune diseases in the clinic. Here, we report the generation and clinical results of a CD40L binding protein, VIB4920, which lacks an Fc domain, therefore avoiding platelet-related safety issues observed with earlier monoclonal antibody therapeutics that targeted CD40L. VIB4920 blocked downstream CD40 signaling events, resulting in inhibition of human B cell activation and plasma cell differentiation, and did not induce platelet aggregation in preclinical studies. In a phase 1 study in healthy volunteers, VIB4920 suppressed antigen-specific IgG in a dose-dependent fashion after priming and boosting with the T-dependent antigen, KLH. Furthermore, VIB4920 significantly reduced circulating Ki67+ dividing B cells, class-switched memory B cells, and a plasma cell gene signature after immunization. In a phase 1b proof-of-concept study in patients with rheumatoid arthritis, VIB4920 significantly decreased disease activity, achieving low disease activity or clinical remission in more than 50% of patients in the two higher-dose groups. Dose-dependent decreases in rheumatoid factor autoantibodies and Vectra DA biomarker score provide additional evidence that VIB4920 effectively blocked the CD40/CD40L pathway. VIB4920 demonstrated a good overall safety profile in both clinical studies. Together, these data demonstrate the potential of VIB4920 to significantly affect autoimmune disease and humoral immune activation and to support further evaluation of this molecule in inflammatory conditions.

1 October 2014 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
VOVaheh Oganesyan
Vaheh Oganesyan
LPLi Peng
Li Peng
MDMelissa M. Damschroder
Melissa M. Damschroder
LCLi Cheng
Li Cheng
ASAgnieszka Sadowska
Agnieszka Sadowska
WDWilliam F. Dall'ACqua
William F. Dall'ACqua
MEDI4893 is a neutralizing human monoclonal antibody that targets α-toxin (AT) and is currently undergoing evaluation in the field of Staphylococcus aureus-mediated diseases. We have solved the crystal structure of MEDI4893 Fab bound to monomeric AT at a resolution of 2.56 Å and further characterized its epitope using various engineered AT variants. We have found that MEDI4893 recognizes a novel epitope in the so-called “rim” domain of AT and exerts its neutralizing effect through a dual mechanism. In particular, MEDI4893 not only sterically blocks binding of AT to its cell receptor but also prevents it from adopting a lytic heptameric trans-membrane conformation.

1 June 2018 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
VOVaheh Oganesyan
Vaheh Oganesyan
LPLi Peng
Li Peng
JBJared S. Bee
Jared S. Bee
JLJohn Li
John Li
SPSamuel R. Perry
Samuel R. Perry
WDWilliam Dall’aCqua
William Dall’aCqua
Pathways of human epidermal growth factor (EGF) receptors are activated upon ligand-dependent or -independent homo- or heterodimerization and their subsequent transphosphorylation. Overexpression of these receptors positively correlates with transphosphorylation rates and increased tumor growth rates. MEDI4276, an anti-human epidermal growth factor receptor 2 (HER2) biparatopic antibody–drug conjugate, has two paratopes within each antibody arm. One, 39S, is aiming at the HER2 site involved in receptor dimerization and the second, single chain fragment (scFv), mimicking trastuzumab. Here we present the cocrystal structure of the 39S Fab–HER2 complex and, along with biophysical and functional assays, determine the corresponding epitope of MEDI4276 and its underlying mechanism of action. Our results reveal that MEDI4276's uniqueness is based first on the ability of its 39S paratope to block HER2 homo- or heterodimerization and second on its ability to cluster the receptors on the surface of receptor-overexpressing cells.

26 June 2024 in Science Translational Medicine
Verified
Journal Article
Closed access
YCYingyun Cai
Yingyun Cai
SDSeme Diallo
Seme Diallo
KRKim Rosenthal
Kim Rosenthal
KRKuishu Ren
Kuishu Ren
DFDaniel J. Flores
Daniel J. Flores
JFJoseph Francica
Joseph Francica
The evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has resulted in variants that can escape neutralization by therapeutic antibodies. Here, we describe AZD3152, a SARS-CoV-2–neutralizing monoclonal antibody designed to provide improved potency and coverage against emerging variants. AZD3152 binds to the back left shoulder of the SARS-CoV-2 spike protein receptor binding domain and prevents interaction with the human angiotensin-converting enzyme 2 receptor. AZD3152 potently neutralized a broad panel of pseudovirus variants, including the currently dominant Omicron variant JN.1 but has reduced potency against XBB subvariants containing F456L. In vitro studies confirmed F456L resistance and additionally identified T415I and K458E as escape mutations. In a Syrian hamster challenge model, prophylactic administration of AZD3152 protected hamsters from weight loss and inflammation-related lung pathologies and reduced lung viral load. In the phase 1 sentinel safety cohort of the ongoing SUPERNOVA study ( ClinicalTrials.gov : NCT05648110), a single 600-mg intramuscular injection of AZD5156 (containing 300 mg each of AZD3152 and cilgavimab) was well tolerated in adults through day 91. Observed serum concentrations of AZD3152 through day 91 were similar to those observed with cilgavimab and consistent with predictions for AZD7442, a SARS-CoV-2–neutralizing antibody combination of cilgavimab and tixagevimab, in a population pharmacokinetic model. On the basis of its pharmacokinetic characteristics, AZD3152 is predicted to provide durable protection against symptomatic coronavirus disease 2019 caused by susceptible SARS-CoV-2 variants, such as JN.1, in humans.

31 October 2015 in Acta Crystallographica Section D Structural Biology
Verified
Journal Article
Open access
PDF file
VOVaheh Oganesyan
Vaheh Oganesyan
YMYariv Mazor
Yariv Mazor
CYChunning Yang
Chunning Yang
KCKimberly E. Cook
Kimberly E. Cook
RWRobert M. Woods
Robert M. Woods
WDWilliam F. Dall'ACqua
William F. Dall'ACqua
The three-dimensional structure of a human IgG1 Fc fragment bound to wild-type human FcγRI is reported. The structure of the corresponding complex was solved at a resolution of 2.4 Å using molecular replacement; this is the highest resolution achieved for an unmutated FcγRI molecule. This study highlights the critical structural and functional role played by the second extracellular subdomain of FcγRI. It also explains the long-known major energetic contribution of the Fc `LLGG' motif at positions 234–237, and particularly of Leu235, via a `lock-and-key' mechanism. Finally, a previously held belief is corrected and a differing view is offered on the recently proposed direct role of Fc carbohydrates in the corresponding interaction. Structural evidence is provided that such glycan-related effects are strictly indirect.

1 September 2005 in Journal of Structural and Functional Genomics
Verified
Journal Article
Closed access
PDF file
SKSung-Hou Kim
Sung-Hou Kim
DSDong Hae Shin
Dong Hae Shin
JLJinyu Liu
Jinyu Liu
VOVaheh Oganesyan
Vaheh Oganesyan
SCShengfeng Chen
Shengfeng Chen
RKRosalind Kim
Rosalind Kim